ArticleScientific reports2025
Bioinformatics analysis of COMMD family in pan-cancer reveals potential biomarkers and therapeutic targets.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The copper-metabolism Murr1 domain (COMMD) protein family plays an essential role in tumours and the immune system. However, the multi-omics characterisation of COMMD family genes and their role in tumour patients has yet to be explored. We collected data from 33 types of cancer and conducted a comprehensive analysis of the expression abnormalities, diagnostic and prognostic roles, subcellular localisation, pathway enrichment, immune microenvironment and immune checkpoint associations of COMMD family genes in these diseases. We also predicted patient responses to immunotherapy using ICIs. Finally, we confirmed the role of COMMD7 in ccRCC and bladder cancer through in vivo and in vitro experiments. We found differential expression and diagnostic biomarker value of the COMMD family of proteins in pan-cancer, and also found that they play a key role in the tumour microenvironment. COMMD proteins are closely related to common immune checkpoints, TMBs and MSIs, and COMMD family proteins can predict immunotherapy response in patients with various cancers. Finally, knockdown of COMMD7 was found to inhibit the progression of ccRCC and bladder cancer cells, as verified by in vivo and in vitro experiments. Our study highlights the great potential of COMMDs as prognostic and immunotherapeutic response biomarkers, which could pave the way for further research into tumour infiltration mechanisms and the therapeutic potential of COMMDs in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.